Actions of Panlax in details
Pharmacology: Panlax is a locally acting laxative from the diphenylmethane derivatives group having a dual action. As a contact laxative, for which also antiresorptive hydragogue effects have been described, Panlax stimulates after hydrolysis in the large intestine, the mucosa of both the large intestine and of the rectum. Stimulation of the mucosa of the large intestine results in colonic peristalsis with promotion of accumulation of water, and consequently electrolytes, in the colonic lumen. This results in a stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool" although its clinical relevance remains to be established.
Pharmacokinetics: Following either oral or rectal administration, Panlax is rapidly hydrolyzed to the active principle bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), mainly by esterases of the enteric mucosa.
Administration as an enteric-coated tablet was found to result in maximum BHPM plasma concentrations between 4-10 hours post-administration whereas, the laxative effect occurred between 6-12 hours post-administration. In contrast, following the administration as a suppository, the laxative effect occurred on average approximately 20 minutes post-administration; in some cases it occurred 45 minutes after administration. The maximum BHPM-plasma concentrations were achieved 0.5-3 hours following the administration as a suppository. Hence, the laxative effect of Panlax does not correlate with the plasma level of BHPM. Instead, BHPM acts locally in the lower part of the intestine, and there is no relationship between the laxative effect and plasma levels of the active moiety. For this reason, Panlax coated tablets are formulated to be resistant to gastric and small intestinal juice. This results in a main release of the drug in the colon, which is the desired site of action.
After oral and rectal administration, only small amounts of the drug are absorbed, and are almost completely conjugated in the intestinal wall and the liver to form the inactive BHPM glucuronide. The plasma elimination half-life of BHPM glucuronide was estimated to be approximately 16.5 hours. Following the administration of Panlax coated tablets, an average of 51.8% of the dose was recovered in the faeces as free BHPM and an average of 10.5% of the dose was recovered in the urine as BHPM glucuronide. Following the administration as a suppository, an average of 3.1% of the dose was recovered as BHPM glucuronide in the urine. Stool contained large amounts of BHPM (90% of the total excretion) in addition to small amounts of unchanged Panlax.
Panlax administration
Oral: Administer with water. Swallow tablet whole; do not break, chew, or crush; do not administer within 1 hour of antacids, milk, or dairy products.
Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut or crush in order to avoid gastric irritation.
Rectal:
Enema: Shake well; remove protective shield, insert tip into rectum with slight side to side movement; squeeze the bottle until nearly all liquid expelled (some liquid will remain in unit after use). Gently remove the unit, a small amount of liquid will remain in unit after use.
Suppository: Remove foil, insert into rectum with pointed end first. Retain in rectum for 15 to 20 minutes.
Panlax pharmacology
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action HalfLytely and Panlax Tablets Bowel Prep Kit induces diarrhea which cleanses the colon. 12.2 Pharmacodynamics Panlax, a stimulant laxative, is hydrolyzed by intestinal brush border enzymes and colonic bacteria to form an active metabolite [bis-(p-hydroxyphenyl) pyridyl-2 methane; (BHPM)] that acts directly on the colonic mucosa to produce colonic peristalsis. 12.3 Pharmacokinetics The osmotic activity of HalfLytely solution results in no net absorption or excretion of ions or water.
References
- DailyMed. "BISACODYL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- NCIt. "Bisacodyl: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
- EPA DSStox. "Bisacodyl: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Panlax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Panlax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported administration
When best can I take Panlax, on an empty stomach, before or after food?ndrugs.com website users have also released a report stating that Panlax should be taken Before food. In any case, this may not be the right description on how you ought to take this Panlax. Kindly visit your doctor for more medical advice in this regard. Click here to see other users view on when best the Panlax can be taken.
| Users | % | ||
|---|---|---|---|
| Before food | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
